Yesterday, the United States Preventive Services Task Force updated recommendations on breast cancer screening, suggesting that women ages 50 to 74 who are at average risk for getting the disease undergo a routine screening mammogram every 2 years. The recommendations were published in the November 17 Annals of Internal Medicine.
Read more > >
-
Compound kills cancer cells by suppressing the Notch signaling pathway
-
Mouse study suggests mechanism to explain earlier trial results in humans
-
A nationwide study in Denmark identifies risk factors for chronic pain after surgery
-
Since 2002, rates of atypical ductal hyperplasia have dropped along with hormone use
-
I131 with CD45 antibody achieves results on par with those in easier-to-treat patients
-
Blocking a protein called MALT1 results in the death of certain lymphoma cells
by Dr. Eric J. (Rocky) Feuer
NCI's Cancer Intervention and Surveillance Modeling Network (CISNET) is a large coordinated program that uses complex, multi-cohort modeling to better understand at the population level the impact of both existing and emerging cancer control interventions—whether they are screening modalities or drug therapies or a multi-modal approach to smoking cessation—on trends in cancer incidence and mortality. Nine years since CISNET was launched, this innovative program is providing important insights on the prevention, diagnosis, and treatment of the four most common cancer types: prostate, lung, colorectal, and breast.
Read more > >
Special Issue on Training
Don’t miss our December 1 special issue on training, which will highlight important resources available through NCI’s intramural and extramural programs to help prepare the oncology workforce for the future.
NCI Cancer Bulletin special issues are some of the most popular among our readers. Past special issues have focused on personalized drug development, cancer imaging, and bioinformatics.
-
Several studies examined why patients who were judged to be good candidates for breast-conserving surgery chose mastectomy instead
-
Will combining lenalidomide and epoetin alfa reduce need for transfusions in anemic MDS patients?
-
At a meeting earlier this month, researchers discussed how to build on this 30 year collaboration in the years ahead
-
- New Treatment for Rare Skin Cancer Approved by FDA
- NCI Web Site Consolidates Supportive and Palliative Care Information
- NCI's Radiation Biology Branch Chief Honored with ASTRO Fellowship
- NIH to Host "Drug Repositioning" Conference Next Month
- 2009 NCI Translational Science Meeting Held
- President's Cancer Panel Explores Genetic Differences in Cancer Burden
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
